Catherine Davidson - Hemagen Diagnostics Insider

HMGN -- USA Stock  

USD 0.02  0.00  0.00%

  Executive
Mrs. Catherine M. Davidson serves as Principal Accounting Officer, Controller of Hemagen Diadnostics, Inc. Mrs. Davidson was appointed Controller of Hemagen in April 2007. Prior to her appointment, Mrs. Davidson served as CFO of Pepco Building Services, Inc. On July 11, 2007, Catherine Davidson was appointed as the Companys Principal Financial Officer and Principal Accounting Officer. For the five years prior to joining Hemagen, Mrs. Davidson served as the Chief Financial Officer of Pepco Building Services, Inc., overseeing the finance and accounting functions of that company and its subsidiaries.
Age: 46  Executive Since 2013      
443-367-5500  http://www.hemagen.com

Management Efficiency

The company has return on total asset (ROA) of (10.27) % which means that it has lost $10.27 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.2) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 5.03 M in liabilities. Hemagen Diagnostics has Current Ratio of 1.05 suggesting that it is not liquid enough and may have problems to pay out its financial obligations when they are due.

Similar Executives

Found 11 records

EXECUTIVE Since

Anna LlovidoMegaworld Corporation
2014
Qi RuanCHINA LIFE INSURANCE LTD
2016
Zhong ZhanCHINA LIFE INSURANCE LTD
1968
Cristina GilFernandezMetro Pacific Investments Corpo
2013
Cheryll SerenoMegaworld Corporation
2018
Johann QuiazonMegaworld Corporation
2017
Rolando SiatelaMegaworld Corporation
N/A
Yong ZhengCHINA LIFE INSURANCE LTD
2013
Mingguang LiCHINA LIFE INSURANCE LTD
2017
Joseph LacsonMetro Pacific Investments Corpo
2016
Jiade LiuCHINA LIFE INSURANCE LTD
2015

Entity Summary

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company was founded in 1985 and is based in Columbia, Maryland. Hemagen Diagnostics operates under Biotechnology classification in USA and traded on OTC Market. It employs 15 people.Hemagen Diagnostics (HMGN) is traded on OTC Market in USA. It is located in 9033 Red Branch Road and employs 15 people.

Hemagen Diagnostics Leadership Team

William Hales, Executive Chairman, CEO and President Chairman of Nominating Committee, Member of Audit Committee and Member of Compensation Committee
Robert Campbell, CFO
Catherine Davidson, Principal Financial Officer, Principal Accounting Officer and Controller
Edward Lutz, Independent Director
Alan Cohen, Independent Director

Stock Performance Indicators

Current Sentiment - HMGN

Hemagen Diagnostics Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Hemagen Diagnostics. What is your judgment towards investing in Hemagen Diagnostics? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
Search macroaxis.com